company background image
THRX

Theseus PharmaceuticalsNasdaqGS:THRX Stock Report

Last Price

US$9.94

Market Cap

US$375.6m

7D

-1.2%

1Y

n/a

Updated

19 Jan, 2022

Data

Company Financials +
THRX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

THRX Stock Overview

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients.

Price History & Performance

Summary of all time highs, changes and price drops for Theseus Pharmaceuticals
Historical stock prices
Current Share PriceUS$9.94
52 Week HighUS$24.54
52 Week LowUS$8.65
Beta0
1 Month Change-1.00%
3 Month Change-38.18%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-46.50%

Recent News & Updates

Shareholder Returns

THRXUS PharmaceuticalsUS Market
7D-1.2%-3.5%-3.5%
1Yn/a7.1%10.2%

Return vs Industry: Insufficient data to determine how THRX performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how THRX performed against the US Market.

Price Volatility

Is THRX's price volatile compared to industry and market?
THRX volatility
THRX Average Weekly Movement22.4%
Pharmaceuticals Industry Average Movement10.6%
Market Average Movement6.6%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.4%

Stable Share Price: THRX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.

Volatility Over Time: Insufficient data to determine THRX's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
201716Tim Clacksonhttps://theseusrx.com

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-variant inhibitor for activating and resistance mutations of the KIT kinase or a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer.

Theseus Pharmaceuticals Fundamentals Summary

How do Theseus Pharmaceuticals's earnings and revenue compare to its market cap?
THRX fundamental statistics
Market CapUS$375.60m
Earnings (TTM)-US$21.54m
Revenue (TTM)n/a

0.0x

P/S Ratio

-17.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
THRX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
ExpensesUS$21.54m
Earnings-US$21.54m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.57
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did THRX perform over the long term?

See historical performance and comparison

Valuation

Is Theseus Pharmaceuticals undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Theseus Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Theseus Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Theseus Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

-38.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: THRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: THRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: THRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: THRX is forecast to have no revenue next year.

High Growth Revenue: THRX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if THRX's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Theseus Pharmaceuticals performed over the past 5 years?

-99.7%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: THRX is currently unprofitable.

Growing Profit Margin: THRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if THRX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare THRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: THRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: THRX has a negative Return on Equity (-23.66%), as it is currently unprofitable.


Financial Health

How is Theseus Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: THRX's short term assets ($91.5M) exceed its short term liabilities ($5.7M).

Long Term Liabilities: THRX's short term assets ($91.5M) exceed its long term liabilities ($903.0K).


Debt to Equity History and Analysis

Debt Level: THRX is debt free.

Reducing Debt: THRX had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: THRX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: THRX has sufficient cash runway for 2.7 years if free cash flow continues to reduce at historical rates of 70.7% each year.


Dividend

What is Theseus Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate THRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate THRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if THRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if THRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of THRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average management tenure


CEO

Tim Clackson (56 yo)

0.67

Tenure

Dr. Timothy P. Clackson, also known as Tim, Ph D., is a Director at Elevation Oncology, Inc. since May 2020. Dr. Clackson serves as the Chief Executive Officer and President at Theseus Pharmaceuticals, Inc...


Leadership Team

Experienced Management: THRX's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.


Board Members

Experienced Board: THRX's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: THRX insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: THRX only recently listed within the past 12 months.


Top Shareholders

Company Information

Theseus Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Theseus Pharmaceuticals, Inc.
  • Ticker: THRX
  • Exchange: NasdaqGS
  • Founded: 2017
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$375.605m
  • Shares outstanding: 37.79m
  • Website: https://theseusrx.com

Number of Employees


Location

  • Theseus Pharmaceuticals, Inc.
  • 245 Main Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 23:51
End of Day Share Price2022/01/19 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.